Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Companion Diagnostics Market Set to Surpass USD 12 Billion by 2031 with a CAGR of 13.2% - Discover Key Insights Now! Valuates Reports

This image opens in the lightbox

News provided by

Valuates Reports

07 May, 2025, 14:15 GMT

Share this article

Share toX

Share this article

Share toX

BANGALORE, India, May 7, 2025 /PRNewswire/ -- Companion Diagnostics Market is Segmented by Type (Immunohistochemistry, Molecular Diagnosis), by Application (Oncology, Cardiovascular, Central Nervous System, Virology).

The Companion Diagnostics Market was estimated to be worth USD 5106 Million in 2024 and is forecast to a readjusted size of USD 12030 Million by 2031 with a CAGR of 13.2% during the forecast period 2024-2030.

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-27J1624/Global_Companion_Diagnostic_Market

Major Factors Driving the Growth of Companion Diagnostics Market:

The companion diagnostics market is a vital segment of precision healthcare, offering tailored treatment strategies based on individual patient profiles. It plays a crucial role in enhancing therapeutic efficacy, minimizing side effects, and streamlining drug development. The market is fueled by the growing prevalence of chronic diseases, increasing demand for personalized medicine, technological advancements, and collaborative efforts between pharmaceutical and diagnostic companies. As healthcare systems globally shift towards more patient-specific approaches, companion diagnostics are becoming central to treatment decisions across various specialties. The continuous evolution of diagnostic platforms and increasing regulatory support ensure a dynamic and expanding market landscape.

Unlock Insights: View Full Report Now! https://reports.valuates.com/market-reports/QYRE-Auto-27J1624/global-companion-diagnostic

TRENDS INFLUENCING THE GROWTH OF THE COMPANION DIAGNOSTICS MARKET:

Next Generation Sequencing (NGS) significantly contributes to the growth of the companion diagnostics market by enabling precise genomic profiling, which is critical for personalized medicine. Its high-throughput capability allows researchers and clinicians to simultaneously analyze multiple genes associated with specific diseases or treatment responses. This comprehensive genetic insight helps in identifying biomarkers that predict a patient's response to targeted therapies. NGS-based companion diagnostics are particularly vital in oncology, where treatment effectiveness varies greatly among individuals. Pharmaceutical companies increasingly collaborate with diagnostic developers to pair NGS-based tests with specific drugs, ensuring optimal patient outcomes. Moreover, NGS improves the speed and accuracy of diagnostics, thereby gaining regulatory approvals and encouraging wider adoption across healthcare systems globally.

Polymerase Chain Reaction (PCR) is a key driver in the companion diagnostics market due to its ability to rapidly and accurately detect genetic mutations and alterations linked to disease progression and drug efficacy. PCR is widely used in clinical laboratories because of its cost-effectiveness, speed, and reliability. Its high sensitivity allows early identification of actionable genetic targets, especially in cancers and infectious diseases, aiding clinicians in selecting the most effective therapies. As pharmaceutical companies aim to match treatments with specific genetic profiles, PCR-based companion diagnostics become essential tools for validating drug efficacy and safety. The continuous development of real-time and digital PCR technologies enhances diagnostic accuracy, further boosting demand in both research and clinical settings.

Pharmaceutical companies are major contributors to the expansion of the companion diagnostics market by integrating diagnostics into drug development pipelines. These companies increasingly rely on companion diagnostics to stratify patients during clinical trials, enhancing treatment efficacy and minimizing adverse effects. This targeted approach not only increases the likelihood of regulatory approval but also improves patient outcomes and market adoption of new drugs. Collaborations between pharma and diagnostic firms are rising, aimed at co-developing tests that are approved simultaneously with therapeutic drugs. As personalized medicine becomes central to treatment protocols, pharmaceutical companies are investing heavily in companion diagnostics to support precision therapies, especially in oncology, immunology, and rare diseases, thereby propelling overall market growth.

The increasing global burden of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions is significantly driving the companion diagnostics market. These diseases often require personalized treatment strategies due to patient-specific variations in drug response. Companion diagnostics help in identifying genetic markers that indicate the effectiveness of a particular therapy, thereby improving treatment outcomes. As the prevalence of these conditions rises, the demand for tests that can match patients with appropriate therapies is also increasing. This drives investment in research and the adoption of advanced diagnostic platforms across hospitals and laboratories, thus fueling the overall market growth.

The shift from a one-size-fits-all approach to individualized treatment is a major factor boosting the companion diagnostics market. Personalized medicine relies heavily on identifying genetic, proteomic, or metabolic markers to determine the most effective treatment for each patient. Companion diagnostics are essential tools in this model, guiding therapy decisions and ensuring optimal drug efficacy. Regulatory agencies also support this approach, as it reduces trial-and-error prescribing and improves safety profiles. As healthcare systems and payers increasingly recognize the long-term cost-effectiveness of personalized therapies, the integration of companion diagnostics into clinical workflows is expanding, promoting sustained market growth.

The development of targeted therapies by pharmaceutical companies is directly boosting the need for companion diagnostics. These therapies are designed to interact with specific molecular targets, making diagnostic tools essential for identifying suitable patients. Without these tests, the effectiveness of targeted drugs cannot be maximized. As oncology, immunology, and infectious diseases witness a surge in targeted drug development, the parallel growth of companion diagnostics becomes inevitable. The success of targeted treatments often hinges on early and accurate diagnosis, positioning companion diagnostics as integral to drug launch strategies and long-term treatment management.

Patients today are more informed and involved in treatment decisions, leading to increased demand for precision-based therapies supported by diagnostic insights. Companion diagnostics empower patients by providing a clear understanding of their genetic profiles and the likelihood of success with specific treatments. This transparency improves trust and compliance, leading to better outcomes. Educational campaigns and digital health platforms have played a key role in disseminating information about personalized therapies. As more patients seek tailored treatments over generic protocols, the role of companion diagnostics becomes more prominent, encouraging further innovation and market growth.

Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-27J1624&lic=single-user

COMPANION DIAGNOSTICS MARKET SHARE:

The companion diagnostics market shows strong regional variations, with North America leading due to its advanced healthcare infrastructure, high R&D investments, and early adoption of precision medicine.

Europe follows closely, supported by favorable regulatory frameworks and increasing collaborations between pharma and diagnostic firms.

In Asia-Pacific, the market is rapidly growing due to rising awareness, expanding healthcare facilities, and increasing prevalence of chronic diseases. Countries like China, Japan, and India are witnessing a surge in demand for genetic testing and cancer diagnostics.

Key Companies:

  • Abbott Laboratories
  • Agilent Technologies
  • Danaher
  • Illumina Inc
  • Myriad Genetics
  • Qiagen NV
  • Thermo Fisher Scientific
  • Roche Holdings
  • Merck
  • Agendia
  • Advanced Cell Diagnostics

Purchase Chapters: https://reports.valuates.com/request/chaptercost/QYRE-Auto-27J1624/Global_Companion_Diagnostic 

SUBSCRIPTION

We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.

DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!

-          Immune in Vitro Diagnostics market was valued at USD 23380 Million in 2023 and is anticipated to reach USD 37310 Million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.

-          Companion Diagnostics for Oncology Market was estimated to be worth USD 4101 Million in 2023 and is forecast to a readjusted size of USD 8392.9 Million by 2030 with a CAGR of 10.8% during the forecast period 2024-2030.

-          Digital Companion Diagnostics Market

-          Companion Diagnostics (CDx) Development Services Market

-          Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market was estimated to be worth USD 9591.9 Million in 2023 and is forecast to a readjusted size of USD 24730 Million by 2030 with a CAGR of 14.7% during the forecast period 2024-2030.

-          Companion Diagnostics Devices Market

-          Circulating Tumor Cell Diagnostics market is projected to grow from USD 5449.1 Million in 2024 to USD 9239.7 Million by 2030, at a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period.

-          Veterinary Health Diagnostics Market was estimated to be worth USD 3152 Million in 2023 and is forecast to a readjusted size of USD 4655.2 Million by 2030 with a CAGR of 5.6% during the forecast period 2024-2030.

-          Companion Cancer Diagnostics Market

-          Companion Animal Diagnosis Market was estimated to be worth USD 2436 Million in 2023 and is forecast to a readjusted size of USD 4256.4 Million by 2030 with a CAGR of 8.3% during the forecast period 2024-2030.

-          Companion Animal Diagnostics Imaging Market was estimated to be worth USD 2660 Million in 2023 and is forecast to a readjusted size of USD 4367.8 Million by 2030 with a CAGR of 7.3% during the forecast period 2024-2030.

DISCOVER OUR VISION: VISIT ABOUT US!

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.

Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.

GET A FREE QUOTE

Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
WhatsApp: +91-9945648335
Website: https://reports.valuates.com
Blog: https://valuatestrends.blogspot.com/
Pinterest: https://in.pinterest.com/valuatesreports/
Twitter: https://twitter.com/valuatesreports
Facebook: https://www.facebook.com/valuatesreports/
YouTube: https://www.youtube.com/@valuatesreports6753
https://www.facebook.com/valuateskorean
https://www.facebook.com/valuatesspanish

https://www.facebook.com/valuatesjapanese

https://valuatesreportspanish.blogspot.com/

https://valuateskorean.blogspot.com/

https://valuatesgerman.blogspot.com/

https://valuatesreportjapanese.blogspot.com/
 

Logo: https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg

Modal title

Also from this source

Brand Licensing Market to Reach USD 470.55 Billion by 2030, Driven by Growth in Apparel, Toys & Entertainment

Brand Licensing Market to Reach USD 470.55 Billion by 2030, Driven by Growth in Apparel, Toys & Entertainment

Brand Licensing Market is Segmented by Type (Apparels, Toys, Accessories, Home Decoration, Software/Video Games, Food and Beverage), by Application...

Pharmaceutical Lab Equipment Market to Hit USD 15.59 Billion by 2031, Driven by R&D and Biopharma Growth

Pharmaceutical Lab Equipment Market to Hit USD 15.59 Billion by 2031, Driven by R&D and Biopharma Growth

Pharmaceutical Lab Equipment Market is Segmented by Type (Pretreatment Type, Reaction Type, Analysis & Test Type), by Application (Research...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Medical Equipment

Medical Equipment

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.